At a Glance
Quickcomparison
Dose Range
Ziconotide (Prialt)
2.4 mcg/day–19.2 mcg/day mcg
BPC-157
250–500 mcg
Frequency
Once daily
Administration
Intrathecal infusion
Subcutaneous injection
Cycle Length
Ongoing/indefinite
4-6 weeks
Onset Speed
Moderate (1-2 weeks)
Evidence Level
Strong human trials (Phase 3 or FDA approved)
Strong preclinical (extensive animal studies)
Efficacy
Benefitratings
Pain Relief
Opioid Alternative
Neuropathic Pain
Primary Benefit
Secondary Benefit
Additional Benefit
Technical Data
Compoundspecifications
Molecular Formula
C102H172N36O32S7
Molecular Weight
2639.2 Da
Half-Life
CSF: 4.6 hours; Plasma: 1.3 hours
Bioavailability
100% intrathecal; does not cross blood-brain barrier systemically
CAS Number
107452-89-1
C62H98N16O22
1419.53 g/mol
4-6 hours
~100% (subcutaneous)
137525-51-0
Protocols
Dosingtiers
starting
2.4 mcg/day
Continuous infusion
Starting point
Ziconotide is pumped directly into the fluid around the spinal cord. It begins at no more than 2.4 mcg per day (0.1 mcg per hour). Starting low and going slow lowers the chance of side effects [6].
standard
Increase up to 2.4 mcg/day per step
No more than 2-3 times per week
Until pain is controlled
The dose is raised slowly, by up to 2.4 mcg per day at a time, and no more than 2 to 3 times a week. The right dose is whatever controls pain without too many side effects [6].
advanced
Up to 19.2 mcg/day
Ongoing/maintenance
The most that should be given is 19.2 mcg per day (0.8 mcg per hour). Many people get relief below this, since slow titration is better tolerated than reaching the maximum quickly [6].
250 mcg
1-2 weeks
A common starting amount in research practice, often injected near the injured area. BPC-157 has no human dose-finding trials, so doses come from animal studies and documented practice [1][2].
250-500 mcg
Twice daily
Commonly used range for tissue and tendon recovery in research practice [1][3].
500 mcg
6-8 weeks
Upper end used in practice for more demanding acute injuries [1][3].
Applications
Bestsuited for
Severe chronic pain management
Ziconotide (Prialt) is particularly well-suited for individuals focused on severe chronic pain management. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Opioid-refractory neuropathic pain
Ziconotide (Prialt) is particularly well-suited for individuals focused on opioid-refractory neuropathic pain. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Cancer-related intractable pain
Ziconotide (Prialt) is particularly well-suited for individuals focused on cancer-related intractable pain. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Reducing systemic opioid dependence
Ziconotide (Prialt) is particularly well-suited for individuals focused on reducing systemic opioid dependence. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Tendon and ligament injuries
Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair
Gut healing
IBS, leaky gut, ulcers, inflammatory bowel conditions - derived from gastric juice, it has a natural affinity for digestive tissue
Muscle injuries
Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression
Joint problems
Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties
Post-surgical recovery
Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms
Safety Profile
Sideeffects
Common
Dizziness
Nausea
Uncommon
Confusion and Memory Impairment
Ataxia and Nystagmus
Serious
Psychiatric Symptoms
Elevated Creatine Kinase and Rhabdomyolysis
Rhabdomyolysis with Acute Renal Failure
Injection site redness
Mild nausea
Headache
Fatigue
Hot/cold sensations
Allergic reaction
Research Status
Safety& evidence
FDA Status
FDA approved for this use
Safety Overview
Ziconotide (Prialt, FDA-approved since 2004) demonstrates favorable safety in intrathecal delivery with dose-dependent adverse effects primarily cognitive/psychiatric: dizziness, confusion, memory impairment, and mood changes in 20-50% of patients depending on infusion rate. Serious risks include meningitis-like aseptic meningitis (rare but documented), cognitive decline requiring dose reduction in ~25% of treated patients, and infection at intrathecal catheter insertion site. Hemodynamic effects (hypotension, dizziness) occur in dose-dependent fashion, necessitating slow titration (starting at 2.4 mcg/day, increasing weekly).
Contraindications
xPre-existing history of psychosis
xInfection at the microinfusion injection site
xUncontrolled bleeding diathesis
xSpinal canal obstruction impairing CSF circulation
Research compound
BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. No FDA approval exists. Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions.
xPregnancy
xBreastfeeding
xActive cancer
xHistory of cancer
Decision Guide
Which isright for you?
Choose Ziconotide (Prialt) if...
Severe chronic pain management
Opioid-refractory neuropathic pain
Cancer-related intractable pain
Reducing systemic opioid dependence
Choose BPC-157 if...
Injury recovery
Post-surgery healing
Chronic pain management
Gut health